Guideline for radioimmunotherapy of rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma

NuklearMedizin

Volumn 43, Issue 5, 2004, Pages 171-176

  Fischer, M ^a,c   Behr, T ^a   Grunwald F ^a   Knapp, W H ^a   Trumper L ^b   Von Schilling, C ^b  

^a Deutsche Gesell F Nuklearmedizin   (Germany)

^b Deutsche Gesell F Hamatologie O ^*

^c KLINIKUM KASSEL   (Germany)

Author keywords

CD20 receptors; Non hodgkin lymphoma; Radioimmunotherapy; Yttrium 90; Zevalin

Indexed keywords

CD20 ANTIGEN; IBRITUMOMAB TIUXETAN; RITUXIMAB; YTTRIUM 90; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

B LYMPHOCYTE; DISEASE COURSE; FOLLOW UP; HEMATOLOGY; HUMAN; ISOTOPE LABELING; MEDICAL DOCUMENTATION; NONHODGKIN LYMPHOMA; ONCOLOGY; PRACTICE GUIDELINE; QUALITY CONTROL; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; ARTICLE; B CELL LYMPHOMA; BLOOD; FOLLICULAR LYMPHOMA; RADIATION DOSE; STANDARD; TISSUE DISTRIBUTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD20; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; QUALITY CONTROL; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; TISSUE DISTRIBUTION;

EID: 7644223382     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625198     Document Type: Review

References (13)

1. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 1999; 15: 1017-25.
2. Griesinger F, Trümper L, Becker W. Radioimmunkonjugate: Therapie von Non-Hodgkin-Lymphomen und kolorektalen Karzinomen. Der Internist 2001; 42: 860-73.
3. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003; 52: 281-96.
4. Juweid ME. Radioimmunotherapy of B-cell Non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 2002; 43: 1507-29.
5. Press OW, Leonard JP, Coiffier B et al. Immunotherapy of Non-Hodgkin's Lymphoma. Hematology 2001; 221-40.
6. 90Y-labeled anti-CD20 monoclonal anitbody. J Nucl Med 2002; 43: 267-72.
7. Wiseman GA, Gordon LI, Multani PS et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336-42.
8. Wiseman GA, Leigh B, Erwin WD et al. Radiation dosimetry results for Zevalin radioimmunotherapy of Rituximab-refractory Non-Hodgkin lymphoma. Cancer 2002; 94: 1349-57.
9. Witzig TE. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2001; 48 (suppl 1): 91-5.
10. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of Yttrium-90-labeled Ibritumomab Tiuxetan radioimmunotherapy versus Rituximab immunotherapy for patiens with relapsed of refractory low-grade, follicular, or transformed B-cell Non-Hodgkin's Lymphoma. J Clin Oncol 2002; 20: 2453-63.
11. Witzig TE, Flinn IW, Gordon LI et al. Treatment with Ibritumomab Tiuxetan radioimmunotherapy in patients with Rituximab-refractory follicular Non-Hodgkin's Lymphoma. J Clin Oncol 2002; 20: 3262-9.
12. Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell Non-Hodgkin's Lymphoma. J Clin Oncol 1999; 17: 3793-803.
13. Witzig TE, White CA, Gordon LI et al. Safety of Yttrium-90 Ibritumomab Tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed Non-Hodgkin's Lymphoma. J Clin Oncol 2003; 21: 1263-70.